Nuvation Bio (id:9944 NUVB)

2.80 USD

Opening hours: 09:30 - 16:00 (Eastern Standard Time: 11/24/2024 9:32:08 PM)

Exchange closed, opens in 11 hours 57 minutes

• 1 day
• 1 week
• 1 month
• 6 months
• 1 year
• All

About Nuvation Bio

Market Capitalization 885.17M

Nuvation Bio Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic candidates for oncology. The company's lead product candidate is NUV-868, a BD2 selective oral small molecule BET inhibitor that epigenetically regulates proteins that control tumor growth and differentiation, including oncogenes comprising c-myc; NUV-1156, an AR binder Xtandi that address advanced stage prostate cancers with the potential to move into earlier lines typically treated with surgical prostatectomy; and drug-drug conjugate (DDC) platform which leverages a novel therapeutic approach within the drug-conjugate class of anti-cancer therapies to deliver anti-cancer therapeutics to cancer cells, as well as NUV-1176, a PARP inhibitor to address ER+ breast and ovarian cancer. The company was founded in 2018 and is headquartered in New York, New York.